Further expanding the indications for French pharma major Sanofi’s (Euronext: SAN) mega-blockbuster Dupixent (dupilumab), the ...

Privately-held UK firm Cycle Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved Harliku ...

Zealand Pharma, a Danish firm focused on the discovery and development of innovative peptide-based medicines, has announced positive topline results from part two of a Phase Ib multiple ascending dose ...

Spanish plasma-derived medicines specialist Grifols (MCE: GRF) announced that the positive Phase III study data on its fibrinogen concentrate, BT524, has been published in eClinicalMedicine, a ...

A reshaped agenda for the Centers for Disease Control and Prevention’s vaccine advisory committee meeting on June 25–26 ...

Japanese drugmaker Mochida Pharmaceutical (TYO: 4534) announced that Thien Thao Pharmaceutical Joint Stock Company, a partner ...

A report published by the Cell & Gene Collective, based on the findings of an expert commission, has offered recommendations to ensure the UK’s leadership in cell and gene therapies (CGTs) and ...

Sanofi (Euronext: SAN) has signed a strategic agreement with health authorities in Abu Dhabi to accelerate vaccine ...

The benefits from Eli Lilly’s Kisulna (donanemab) remain too small to justify the additional cost to the National Health Service (NHS), said the UK health technology assessor the National Institute ...

This office will serve as Celltrion’s central hub for UK operations and places the firm among a growing list of life sciences companies including Regeneron, Amgen, Gilead Sciences and Daiichi Sankyo ...

Symbiotic.blue, the UK’s newest Techbio company has launched to innovate a next-generation artificial intelligence-driven ...

Caris Life Sciences shares ended trading at $28 per share on Wednesday, marking a 33% increase from its initial public offering (IPO) price of $21 per share.